nach oben

Erschienen in:

04.04.2017 | Antidepressiva | Zertifizierte Fortbildung

Metabolische Nebenwirkungen von Psychopharmaka — Teil 2

Substanzspezifische Betrachtung und therapeutische Möglichkeiten

verfasst von: René Zeiss, Prof. Dr. med. Bernhard J. Connemann, PD Dr. med. Maximilian Gahr, M.A. phil.

Erschienen in: DNP – Die Neurologie & Psychiatrie | Ausgabe 4/2017

Einloggen, um Zugang zu erhalten

Zusammenfassung

Zahlreiche Psychopharmaka sowohl aus dem Bereich der Antidepressiva als auch der Antipsychotika sind mit metabolischen unerwünschten Arzneimittelwirkungen (UAW) assoziiert. Der zweite Teil unseres Beitrags befasst sich mit dem Risiko für Gewichtszunahme und für andere metabolische UAW im Zusammenhang mit konkreten Wirkstoffen. Zugleich werden die gegenwärtig verfügbaren therapeutischen Maßnahmen bei psychopharmakaassoziierten metabolischen UAW erläutert.

Weiden PJ, Mackell JA, McDonnell DD. Obesity as a risk factor for antipsychotic noncompliance. Schizophr Res 2004 Jan 1;66(1):51–57.CrossRefPubMed

Goethe JW, Woolley SB, Cardoni AA, Woznicki BA, Piez DA. Selective serotonin reuptake inhibitor discontinuation: side effects and other factors that influence medication adherence. J Clin Psychopharmacol 2007 Oct;27(5):451–458.CrossRefPubMed

The GBD 2013 OC, Ng M, Fleming T, Robinson M, Thomson B, Graetz N, et al. Global, regional and national prevalence of overweight and obesity in children and adults 1980-2013: A systematic analysis. Lancet (London, England) 2014 05/29;384(9945):766–781.CrossRef

Gahr M, Connemann BJ, Cabanis M, Denoix N. Metabolische Nebenwirkungen von Psychopharmaka. Eine Analyse der Daten aus Fachinformationen. Nervenheilkunde 2016;35(9):559–569.

Ulrich Schwabe DP editor. Arzneiverordnungs-Report 2016. 1st ed.: Springer-Verlag Berlin Heidelberg; 2016.

Bak M, Fransen A, Janssen J, van Os J, Drukker M. Almost All Antipsychotics Result in Weight Gain: A Meta-Analysis. PLoS ONE 2014 04/24;9(4):e94112.CrossRefPubMedPubMedCentral

Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999 Nov;156(11):1686–1696.PubMed

Tardy M, Huhn M, Kissling W, Engel RR, Leucht S. Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia. Cochrane Database of Systematic Reviews 2014(7).

Dold M, Samara MT, Li C, Tardy M, Leucht S. Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders. Cochrane Database of Systematic Reviews 2015(1).

10.

Rummel-Kluge C, Komossa K, Schwarz S, Hunger H, Schmid F, Lobos CA, et al. Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res 2010 Nov;123(2-3):225–233.CrossRefPubMedPubMedCentral

11.

Leucht S, Cipriani A, Spineli L, Mavridis D, Örey D, Richter F, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. The Lancet 2013 2016/12;382(9896):951–962.CrossRef

12.

Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. The Lancet 2009 1/3–9;373(9657):31–41.CrossRef

13.

Uher R, Mors O, Hauser J, Rietschel M, Maier W, Kozel D, et al. Changes in body weight during pharmacological treatment of depression. Int J Neuropsychopharmacol 2011 Apr;14(3):367–375.CrossRefPubMed

14.

Ferguson JM, Feighner JP. Fluoxetine-induced weight loss in overweight non-depressed humans. Int J Obes 1987;11 Suppl 3:163–170.PubMed

15.

Levine LR, Rosenblatt S, Bosomworth J. Use of a serotonin re-uptake inhibitor, fluoxetine, in the treatment of obesity. Int J Obes 1987;11 Suppl 3:185–190.PubMed

16.

Blumenthal SR, Castro VM, Clements CC, Rosenfield HR, Murphy SN, Fava M, et al. An electronic health records study of long-term weight gain following antidepressant use. JAMA Psychiatry 2014 Aug;71(8):889–896.CrossRefPubMed

17.

Serretti A, Mandelli L. Antidepressants and body weight: a comprehensive review and meta-analysis. J Clin Psychiatry 2010 Oct;71(10):1259–1272.CrossRefPubMed

18.

Arterburn D, Sofer T, Boudreau DM, Bogart A, Westbrook EO, Theis MK, et al. Long-Term Weight Change after Initiating Second-Generation Antidepressants. J Clin Med 2016 Apr 13;5(4):10.3390/jcm5040048.

19.

McKnight RF, Adida M, Budge K, Stockton S, Goodwin GM, Geddes JR. Lithium toxicity profile: a systematic review and meta-analysis. The Lancet 2012 2017/01;379(9817):721–728.CrossRef

20.

Bowden CL, Mosolov S, Hranov L, Chen E, Habil H, Kongsakon R, et al. Efficacy of valproate versus lithium in mania or mixed mania: a randomized, open 12-week trial. Int Clin Psychopharmacol 2010 Mar;25(2):60–67.CrossRefPubMed

21.

Dent R, Blackmore A, Peterson J, Habib R, Kay GP, Gervais A, et al. Changes in Body Weight and Psychotropic Drugs: A Systematic Synthesis of the Literature. PLOS ONE 2012 06/15;7(6):e36889.CrossRefPubMedPubMedCentral

22.

Morrell MJ, Isojarvi J, Taylor AE, Dam M, Ayala R, Gomez G, et al. Higher androgens and weight gain with valproate compared with lamotrigine for epilepsy. Epilepsy Res 2003 May;54(2-3):189–199.CrossRefPubMed

23.

Pylvänen V, Pakarinen A, Knip M, Isojärvi J. Insulin-related metabolic changes during treatment with valproate in patients with epilepsy. Epilepsy Behav 2006 May;8(3):643–648.CrossRefPubMed

24.

Biton V, Mirza W, Montouris G, Vuong A, Hammer AE, Barrett PS. Weight change associated with valproate and lamotrigine monotherapy in patients with epilepsy. Neurology 2001 Jan 23;56(2):172–177.CrossRefPubMed

25.

Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes. Diabetes Care 2004 01/27;27(2):596.

26.

Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde. Behandlungsleitlinie Schizophrenie. 2006;1(Interdisziplinäre S3-Praxisleitlinien).

27.

DGPPN, BÄK, KBV, AWMF, AkdÄ, BPtK, BApK, DAGSHG, DEGAM, DGPM, DGPs, DGRW (Hrsg.). für die Leitliniengruppe Unipolare Depression*. S3-Leitlinie/Nationale VersorgungsLeitlinie Unipolare Depression - Langfassung, 2. Auflage, Version 1, November 2015. Available from: www.depression.versorgungsleitlinien.de; [cited: 30.10.2016]; DOI: 10.6101/AZQ/000262.

28.

Stroup TS, McEvoy JP, Ring KD, Hamer RH, LaVange LM, Swartz MS, et al. A Randomized Trial Examining the Effectiveness of Switching From Olanzapine, Quetiapine, or Risperidone to Aripiprazole to Reduce Metabolic Risk: Comparison of Antipsychotics for Metabolic Problems (CAMP). Am J Psychiatry 2011 09/01; 2017/01;168(9):947–956.CrossRefPubMedPubMedCentral

29.

Mukundan A, Faulkner G, Cohn T, Remington G. Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems. Cochrane Database of Systematic Reviews 2010(12).

30.

Green CA, Yarborough BJ, Leo MC, Yarborough MT, Stumbo SP, Janoff SL, et al. The STRIDE weight loss and lifestyle intervention for individuals taking antipsychotic medications: a randomized trial. Am J Psychiatry 2015 Jan;172(1):71–81.CrossRefPubMed

31.

Green CA, Yarborough BJ, Leo MC, Stumbo SP, Perrin NA, Nichols GA, et al. Weight maintenance following the STRIDE lifestyle intervention for individuals taking antipsychotic medications. Obesity (Silver Spring) 2015 Oct;23(10):1995–2001.CrossRef

32.

Daumit GL, Dickerson FB, Wang N, Dalcin A, Jerome GJ, Anderson CAM, et al. A Behavioral Weight-Loss Intervention in Persons with Serious Mental Illness. N Engl J Med 2013 04/25; 2017/01;368(17):1594–1602.CrossRefPubMedPubMedCentral

33.

Gross C, Blasey CM, Roe RL, Belanoff JK. Mifepristone reduces weight gain and improves metabolic abnormalities associated with risperidone treatment in normal men. Obesity (Silver Spring) 2010 Dec;18(12):2295–2300.CrossRef

34.

Gross C, Blasey CM, Roe RL, Allen K, Block TS, Belanoff JK. Mifepristone treatment of olanzapine-induced weight gain in healthy men. Adv Ther 2009 Oct;26(10):959–969.CrossRefPubMed

35.

Richards M, Chiba S, Ninomiya M, Wakabayasi C, Kunugi H. Inhibition of olanzapine-induced weight gain by the retinoid analog AM-80. Pharmacopsychiatry 2013 Nov;46(7):267–273.CrossRefPubMed

36.

Fiedorowicz JG, Miller DD, Bishop JR, Calarge CA, Ellingrod VL, Haynes WG. Systematic Review and Meta-analysis of Pharmacological Interventions for Weight Gain from Antipsychotics and Mood Stabilizers. Curr Psychiatry Rev 2012 Feb 1;8(1):25–36.CrossRefPubMedPubMedCentral

37.

Tchoukhine E, Takala P, Hakko H, Raidma M, Putkonen H, Rasanen P, et al. Orlistat in clozapine- or olanzapine-treated patients with overweight or obesity: a 16-week open-label extension phase and both phases of a randomized controlled trial. J Clin Psychiatry 2011 Mar;72(3):326–330.CrossRefPubMed

38.

Wu R, Zhao J, Guo X, He Y, Fang M, Guo W, et al. Metformin Addition Attenuates Olanzapine-Induced Weight Gain in Drug-Naive First-Episode Schizophrenia Patients: A Double-Blind, Placebo-Controlled Study. Am J Psychiatry 2008 03/01; 2017/01;165(3):352–358.CrossRefPubMed

39.

Wang M, Tong J, Zhu G, Liang G, Yan H, Wang X. Metformin for treatment of antipsychotic-induced weight gain: A randomized, placebo-controlled study. Schizophr Res 2012 6;138(1):54–57.CrossRefPubMed

40.

Jarskog LF, Hamer RM, Catellier DJ, Stewart DD, Lavange L, Ray N, et al. Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder. Am J Psychiatry 2013 Sep;170(9):1032–1040.CrossRefPubMed

41.

Kramer CK, Leitao CB, Pinto LC, Canani LH, Azevedo MJ, Gross JL. Efficacy and safety of topiramate on weight loss: a meta-analysis of randomized controlled trials. Obes Rev 2011 May;12(5):e338–47.CrossRefPubMed

42.

Mahmood S, Booker I, Huang J, Coleman CI. Effect of topiramate on weight gain in patients receiving atypical antipsychotic agents. J Clin Psychopharmacol 2013 Feb;33(1):90–94.CrossRefPubMed

43.

Correll CU, Maayan L, Kane J, Hert MD, Cohen D. Efficacy for Psychopathology and Body Weight and Safety of Topiramate-Antipsychotic Cotreatment in Patients With Schizophrenia Spectrum Disorders: Results From a Meta-Analysis of Randomized Controlled Trials. J Clin Psychiatry 2016 Jun;77(6):e746–56.CrossRefPubMed

44.

Zheng W, Xiang YT, Xiang YQ, Li XB, Ungvari GS, Chiu HF, et al. Efficacy and safety of adjunctive topiramate for schizophrenia: a meta-analysis of randomized controlled trials. Acta Psychiatr Scand 2016 Nov;134(5):385–398.CrossRefPubMed

Titel: Metabolische Nebenwirkungen von Psychopharmaka — Teil 2
Substanzspezifische Betrachtung und therapeutische Möglichkeiten
verfasst von: René Zeiss
Prof. Dr. med. Bernhard J. Connemann
PD Dr. med. Maximilian Gahr, M.A. phil.
Publikationsdatum: 04.04.2017
Verlag: Springer Medizin
Schlagwörter: Antidepressiva
Antipsychotika
Metformin
Antidepressiva
Antipsychotika
Aripiprazol
Olanzapin
Erschienen in: DNP – Die Neurologie & Psychiatrie / Ausgabe 4/2017
Print ISSN: 2731-8168
Elektronische ISSN: 2731-8176
DOI: https://doi.org/10.1007/s15202-017-1495-z

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2017

Bipolare Depression: Bupropion genauso riskant wie andere Antidepressiva

Gibt es ein bipolares Prodrom?

Wann sollte man Cholinesterasehemmer absetzen?

ADHS: Affektstörungen in den Griff bekommen

Sterbegeld muss versteuert werden

Weichenstellungen für die Zukunft